Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CV Sciences (CVSI) Cash & Equivalents (2016 - 2025)

CV Sciences' Cash & Equivalents history spans 15 years, with the latest figure at $278000.0 for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 38.77% to $278000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $278000.0, a 38.77% decrease, with the full-year FY2025 number at $278000.0, down 38.77% from a year prior.
  • Cash & Equivalents hit $278000.0 in Q4 2025 for CV Sciences, down from $381000.0 in the prior quarter.
  • Over the last five years, Cash & Equivalents for CVSI hit a ceiling of $5.2 million in Q1 2021 and a floor of $278000.0 in Q4 2025.
  • Historically, Cash & Equivalents has averaged $1.3 million across 5 years, with a median of $979000.0 in 2024.
  • Biggest five-year swings in Cash & Equivalents: surged 115.55% in 2023 and later tumbled 71.78% in 2024.
  • Tracing CVSI's Cash & Equivalents over 5 years: stood at $1.4 million in 2021, then crashed by 55.56% to $611000.0 in 2022, then surged by 115.55% to $1.3 million in 2023, then crashed by 65.53% to $454000.0 in 2024, then tumbled by 38.77% to $278000.0 in 2025.
  • Business Quant data shows Cash & Equivalents for CVSI at $278000.0 in Q4 2025, $381000.0 in Q3 2025, and $886000.0 in Q2 2025.